IMRX Immuneering Corp

NEUTRAL Impact: 3/10 Institutional Cluster
Horizon weeks Processed 3d 22h ago
Institutional cluster: 5 buyers, 0 sellers (bullish)

Executive Summary

Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) significantly increased their IMRX positions in Q3 2025, with aggregate holdings rising from $6.8M to $86.5M — a net addition of $79.7M. Fidelity alone added $60.8M, including a massive 3,876% share increase. The cluster is entirely passive/index-driven, reflecting likely index reconstitution or inclusion in a new benchmark, not active fundamental conviction.

Key Financial Metrics

Direction
accumulating
Buy Value
$86.5M
Net Flow
$79.7M

Institutional Positions

Net institutional flow: $79.7M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
Fidelity DOUBLED +3876% $61.5M $60.8M
Vanguard DOUBLED +128.5% $16.9M $13.3M
BlackRock ADD +61.1% $4.8M $3.3M
Morgan Stanley ADD +46.6% $2.1M $1.4M
State Street ADD +77.6% $1.2M $882.0K

Actionable Insight

The cluster is entirely passive/index-driven, likely reflecting IMRX's inclusion in a new index or benchmark rebalancing, not active fundamental conviction. With historical IMRX reports showing a -7.58% average T+20 return and only 25% win rate, traders should not interpret this as a bullish signal. Monitor for any active manager 13F filings in subsequent quarters for genuine conviction signals.

Key Facts

  • 5 institutions added $79.7M net to IMRX positions in Q3 2025, with zero sellers
  • Fidelity led with a $60.8M increase (3,876% share growth to 8.79M shares)
  • All buyers are mega-passive/index funds (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley)
  • No active managers or hedge funds participated in the cluster
  • Historical reports on IMRX show a -7.58% average T+20 return and only 25% win rate

Financial Impact

5 institutions accumulated $79.7M in new positions, bringing total disclosed holdings to $86.5M

institutional ownershipfloat

Risk Factors

  • Passive buying provides no fundamental thesis — positions may be unwound at next rebalance
  • Historical IMRX reports show poor post-filing performance (-7.58% avg T+20)
  • 13F data is 45+ days stale; positions may have already been reduced

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-IMRX-2025-Q3
6 reports for IMRX
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+1▲ +6.31%Jun 1, 2026
Filters
Rows
Reports for IMRX — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
NEUTRAL ★ 3/10
$3.90 awaiting T+1awaiting T+1
Jun 1, 2026
13d ago
8-K
BULLISH ★ 7/10
$4.28 $4.55▲ +6.31%▲ +7.00%
May 15, 2026
4w ago
Press Release
BULLISH ★ 7/10
$5.16 $4.87▼ −5.62%▼ −5.56%
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 7/10
$5.89 $6.13▲ +4.07%▲ +4.47%
Apr 20, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$5.55 $5.89▲ +6.13%▲ +5.11%
Mar 6, 2026
14w ago
Press Release
BULLISH ★ 8/10
$5.33 $5.62▲ +5.44%▲ +4.59%
Showing 6 of 6

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access